Tackling antimicrobial resistance (AMR) requires a one health approach that joins the dots between the human, animal, and environmental drivers, consequences, and data.
While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
